Litigation Details for Newron Pharmaceuticals S.p.A v. MSN Laboratories Private Limited (D. Del. 2021)
✉ Email this page to a colleague
Newron Pharmaceuticals S.p.A v. MSN Laboratories Private Limited (D. Del. 2021)
| Docket | ⤷ Sign Up | Date Filed | 2021-06-10 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 8,076,515; 8,278,485; 8,283,380 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Newron Pharmaceuticals S.p.A v. MSN Laboratories Private Limited
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Newron Pharmaceuticals S.p.A v. MSN Laboratories Private Limited (D. Del. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2023-04-14 | 249 | Opinion - Memorandum Opinion | infringement of U.S. Patent No. 8,076,515 ("the '515 patent"), U.S. Patent No. 8,278,485 (&…the '485 patent"), and U.S. Patent No. 8,283,380 ("the '380 patent"). Before…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which…quot;A claim in a patent provides the metes and bounds of the right which the patent confers on the patentee…that inform patent law." Id. The ultimate question of the proper construction of a patent is a question | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
